You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Ovarian cancer

Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy

  • Technology appraisal guidance
  • Reference number: TA908
  • Published:  05 July 2023
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence

  • Evaluation report

  • TA908 Appraisal consultation committee papers  (PDF 4.33 MB)

    Published:
    05 July 2023
  • TA908 Final appraisal determination committee papers  (PDF 769 KB)

    Published:
    05 July 2023
  • TA620 Appraisal consultation committee papers (PDF 12.21 MB)

    Published:
    05 July 2023
  • TA620 Final appraisal determination committee papers (PDF 2.19 MB)

    Published:
    05 July 2023
  • Other supporting evidence

  • TA620 Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer: committee discussion

Back to top